Format
Items per page
Sort by

Send to:

Choose Destination

Results: 7

1.

Obtained effect size as a function of sample size in approved antidepressants: a real-world illustration in support of better trial design.

Gibertini M, Nations KR, Whitaker JA.

Int Clin Psychopharmacol. 2012 Mar;27(2):100-6. doi: 10.1097/YIC.0b013e32834f504f.

PMID:
22233698
2.

Evidence for efficacy and tolerability of vilazodone in the treatment of major depressive disorder: a randomized, double-blind, placebo-controlled trial.

Rickels K, Athanasiou M, Robinson DS, Gibertini M, Whalen H, Reed CR.

J Clin Psychiatry. 2009 Mar;70(3):326-33. Epub 2009 Mar 10.

PMID:
19284933
3.
4.

Why the Hamilton Depression Rating Scale endures.

Bech P, Engelhardt N, Evans KR, Gibertini M, Kalali AH, Kobak KA, Lipsitz JD, Williams JB, Pearson JD, Rothman M.

Am J Psychiatry. 2005 Dec;162(12):2396; author reply 2397-8. No abstract available.

PMID:
16330618
5.

Sustained efficacy of gepirone-IR in major depressive disorder: a double-blind placebo substitution trial.

Amsterdam JD, Brunswick DJ, Gibertini M.

J Psychiatr Res. 2004 May-Jun;38(3):259-65.

PMID:
15003431
6.

A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone.

Robinson DS, Sitsen JM, Gibertini M.

Clin Ther. 2003 Jun;25(6):1618-33. Review.

PMID:
12860488
7.

Gepirone extended-release: new evidence for efficacy in the treatment of major depressive disorder.

Feiger AD, Heiser JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JM, Gibertini M.

J Clin Psychiatry. 2003 Mar;64(3):243-9.

PMID:
12716264
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk